…বাংলা
Barlekha Today logo
All the big stories — in your language, updated every 15 minutes
Home › Europe › News
Europe

Drug-resistant Klebsiella infections surge 72% in European hospitals, EU disease agency warns

Staff Reporter

A dangerous drug-resistant bacterium is surging in European hospitals, spreading between patients and becoming increasingly harder to treat, the EU's disease agency has warned. According to the latest reports from the European Centre for Disease Prevention and Control (ECDC), released on Wednesday, cases of bloodstream infections caused by treatment-resistant Klebsiella pneumoniae increased by 72% between 2019 and 2025.

The rise runs directly against Europe's set target, which was to cut such infection rates by 5% by 2030. The ECDC says the bacterium is spreading between patients and is becoming increasingly harder to treat.

Infections linked to the bacterium have a high mortality rate, typically between 40% and 70%. Analyses show that several of its strains are becoming resistant to nearly all antibiotics, including new ones, and can cause severe illness and death.

Christian Giske, who leads this work at the ECDC, told a press briefing that the findings on treatment-resistant Klebsiella pneumoniae were 'the biggest concern' among all the data collected on superbugs in Europe over the past year. He said antimicrobial resistance is a 'major public health threat' for Europe, estimated to kill 35,000 people in the EU, Iceland and Norway every year.

The picture is not the same everywhere, however. Bloodstream infections caused by the better-known hospital-acquired superbug MRSA, or drug-resistant Staphylococcus aureus, were 19% lower in 2025 than in 2019, surpassing the target of reducing them by 15% by 2030.

By contrast, E. coli drug-resistant infections are also proving difficult to drive down. Against a target of reducing them by 10% by 2030, the EU saw a 16.4% increase between 2019 and 2025. Over the same period, antibiotic consumption dropped by only 5%, well below the 20% reduction target. The proportion of antibiotics in use that are the correct types reached 62.5% in 2025, against a goal of at least 65%.

Giske said Klebsiella is a gut bacterium and may have more powerful reservoirs in the body. What works for MRSA might not be sufficient for Klebsiella, he said, and adherence to infection prevention and control needs to be even higher to contain the problem. The ECDC called for stronger hand hygiene, correct use of personal protective equipment such as gloves, and effective environmental cleaning and disinfection.

ECDC Director Pamela Rendi-Wagner said in a statement that Europe is still behind on several of the EU's 2030 targets to counter antimicrobial resistance. She said genomic surveillance helps authorities assess more quickly how the resistant bacteria are spreading, which means action can be taken sooner to stop transmission, treatment decisions can be guided more effectively, and the places where new antibiotics are most urgently needed can be identified.

The reports come as Europe's new pharmaceutical legislation is set to be signed into law in December. The legislation includes measures to boost the discovery and development of new antibiotics.

Get the news firstNew stories in your inbox — subscribe free.

More in Europe